Physician profile
Gregory Singleton
NPI 1013953330
$531.97
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $16.15 · 2021: $19.88 · 2022: $47.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $156.17 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $152.23 | 2019-2021 | |
| Novo Nordisk INC | $118.65 | 2019 | |
| Lilly USA, LLC | $36.11 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.15 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.68 | 2019 | |
| Pfizer INC. | $10.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Singleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.